Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2016 3
2017 2
2019 2
2020 7
2021 6
2022 2
2023 8
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy.
Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O. Ghisoni E, et al. Among authors: latifyan s. Eur J Cancer. 2021 May;149:153-164. doi: 10.1016/j.ejca.2021.03.010. Epub 2021 Apr 14. Eur J Cancer. 2021. PMID: 33865201 Free article.
[2021 Oncology update].
Meyer ML, Chrysou K, Stamatiou A, Gilabert M, Herrera Gomez RG, Latifyan S, Masmoudi S, Mederos N, Perrinjaquet C, Berthold D, Bouchaab H, Cristina V, Digklia A, Michielin O, Orcurto A, Sarivalasis A, Stravodimou A, Wagner AD, Zaman K, Peters S, Jankovic J. Meyer ML, et al. Among authors: latifyan s. Rev Med Suisse. 2022 Feb 2;18(767):182-186. doi: 10.53738/REVMED.2022.18.767.182. Rev Med Suisse. 2022. PMID: 35107893 French.
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma.
Chiffelle J, Barras D, Pétremand R, Orcurto A, Bobisse S, Arnaud M, Auger A, Rodrigo BN, Ghisoni E, Sauvage C, Saugy D, Michel A, Murgues B, Fahr N, Imbimbo M, Ochoa de Olza M, Latifyan S, Crespo I, Benedetti F, Genolet R, Queiroz L, Schmidt J, Homicsko K, Zimmermann S, Michielin O, Bassani-Sternberg M, Kandalaft LE, Dafni U, Corria-Osorio J, Trueb L, Dangaj Laniti D, Harari A, Coukos G. Chiffelle J, et al. Among authors: latifyan s. Immunity. 2024 Oct 8;57(10):2466-2482.e12. doi: 10.1016/j.immuni.2024.08.014. Epub 2024 Sep 13. Immunity. 2024. PMID: 39276771
Physical approaches to treat glioblastoma.
Latifyan S, de Micheli R, Hottinger AF. Latifyan S, et al. Curr Opin Oncol. 2020 Nov;32(6):640-649. doi: 10.1097/CCO.0000000000000689. Curr Opin Oncol. 2020. PMID: 32925205 Review.
[Oncology: what's new in 2022].
Nguyen-Ngoc T, Abdelhamid K, Degrauwe N, Galland S, Serena A, Christofis M, Mederos N, Bouchaab H, Diciolla A, Dris N, Orcurto A, Perrinjaquet C, Schnetz M, Latifyan S, Wetterwald L, Herrera Gómez RG, Cristina V, Sarivalasis A, Michielin O, Berthold D, Digklia A, Wagner AD, Zaman K, Peters S, Stravodimou A. Nguyen-Ngoc T, et al. Among authors: latifyan s. Rev Med Suisse. 2023 Jan 18;19(N° 809-10):52-57. doi: 10.53738/REVMED.2023.19.809-10.52. Rev Med Suisse. 2023. PMID: 36660838 French.
[Oncology: what's new in 2023].
Jankovic J, Abdelhamid K, Berthold D, Desbaillets N, Bouchaab H, Dei Tos G, Demicheli R, Diciolla A, Digklia A, Ferraro DA, Florez L, Galli-Vareia I, Hottinger A, Latifyan S, Liapi A, Mederos N, Giacomuzzi Moore B, Sakr R, Stamatiou A, Wagner AD, Peters S, Sarivalasis A, Vanniere F, Zaman K, Stravodimou A. Jankovic J, et al. Among authors: latifyan s. Rev Med Suisse. 2024 Jan 17;20(856-7):80-87. doi: 10.53738/REVMED.2024.20.856-7.80. Rev Med Suisse. 2024. PMID: 38231107 French.
Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
Vicino A, Hottinger AF, Latifyan S, Boughdad S, Becce F, Prior JO, Kuntzer T, Brouland JP, Dunet V, Obeid M, Théaudin M. Vicino A, et al. Among authors: latifyan s. J Neurol. 2024 Apr;271(4):1947-1958. doi: 10.1007/s00415-023-12134-x. Epub 2023 Dec 23. J Neurol. 2024. PMID: 38141128 Free PMC article. Review.
[Locally advanced and metastatic melanoma : novelties].
Huber A, Latifyan S, Nikolopoulou A, Homicsko K, Berthod G, Michielin O, Özdemir BC. Huber A, et al. Among authors: latifyan s. Rev Med Suisse. 2020 May 27;16(695):1092-1097. Rev Med Suisse. 2020. PMID: 32462837 Review. French.
Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
Joo V, Abdelhamid K, Noto A, Latifyan S, Martina F, Daoudlarian D, De Micheli R, Pruijm M, Peters S, Hullin R, Gaide O, Pantaleo G, Obeid M. Joo V, et al. Among authors: latifyan s. Nat Commun. 2024 Apr 30;15(1):3664. doi: 10.1038/s41467-024-47965-3. Nat Commun. 2024. PMID: 38693123 Free PMC article.
34 results